Connect Biopharma Holdings Limited (CNTB) Stock Price & Analysis
Connect Biopharma Holdings Limited (CNTB) closed at USD 0.91 on Thursday, October 15, 2026, down 0.31% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.91; the Oct 15, 2026 session ranged USD 0.88–0.93 on volume of 1,513,305 shares. Market capitalization is $57.07M, with a 52-week range of USD 0.85–3.82 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CNTB.md
Key facts (CNTB)
- Last four reported quarters (through Jun 30, 2026): revenue $3.0M, net income -$69.0M (-2336.3% margin), free cash flow -$60.6M (SEC filings).
- Analysts: Buy (mean 1.88 on a 1–5 scale) (8 analysts), mean target USD 5.88 (range 4–9).
- Total return with dividends: 1Y -50.5% vs S&P 500 +18.1%; 5Y -94.7% vs S&P 500 +85.1%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CNTB)
| USD | FY2024 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|
| Revenue | $0K | $26.0M | $64K | $3.0M |
| Operating income | -$69.1M | -$22.5M | -$58.1M | -$70.4M |
| Net income | -$62.1M | -$15.6M | -$55.5M | -$69.0M |
| EPS (diluted) | -$1.13 | -$0.28 | -$1.00 | — |
| Free cash flow | -$47.8M | -$24.4M | -$51.6M | -$60.6M |
| Operating margin | — | -86.2% | -90740.6% | -2384.5% |
| Net margin | — | -60.0% | -86687.5% | -2336.3% |
| Revenue growth | — | — | -99.8% | — |
| Cash + short-term investments | $118M | $93.7M | $44.3M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CNTB)
P/S 19.3x · P/B 2.1x · FCF yield -106.25% · Earnings yield -120.89%
Analysts (CNTB)
Consensus Buy (mean 1.88 on a 1–5 scale), 8 analysts; mean target USD 5.88 (low 4, high 9).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-08 | HC Wainwright & Co. | Reiterated | Buy | $7 |
| 2026-10-02 | HC Wainwright & Co. | Reiterated | Buy | $7 |
| 2026-09-30 | BTIG | Target lowered | Buy | $10 → $5 |
| 2026-09-22 | Oppenheimer | Target lowered | Outperform | $8 → $5 |
| 2026-09-17 | HC Wainwright & Co. | Reiterated | Buy | $7 |
| 2026-09-16 | Canaccord Genuity | Target lowered | Buy | $7 → $6 |
| 2026-09-15 | BTIG | Reiterated | Buy | $10 |
| 2026-07-09 | Oppenheimer | Initiated | Outperform | $8 |
| 2026-06-26 | Piper Sandler | Initiated | Neutral → Overweight | $7 |
| 2026-06-25 | HC Wainwright & Co. | Reiterated | Buy | $7 |
Total return (dividends reinvested) (CNTB)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -50.5% | -94.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -50.6% | -44.4% |
| Volatility (annualized) | 104.3% | 117.4% |
| Max drawdown | -76.4% (Mar 2026→Oct 2026) | -96.4% (Oct 2021→May 2022) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 0.91 |
|---|---|
| Change | ▼ 0.31% (down) |
| Previous Close | USD 0.91 |
| Open | USD 0.89 |
| Day Range | USD 0.88 – 0.93 |
| 52-Week Range | USD 0.85 – 3.82 |
| Volume | 1,513,305 shares |
| Market Cap | $57.07M |
| Exchange | NGM |
Technical Analysis (CNTB)
Nexqual's technical model rates CNTB "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 32.77 (neutral) |
| vs SMA50 | Below (USD 1.69) |
| MACD | -0.22 (negative) |
Analyst Ratings (CNTB)
Wall Street analysts rate CNTB "Buy" based on 8 analysts, with a mean price target of USD 5.88 (range USD 4–9), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 5.88 |
| High Target | USD 9 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (CNTB)
| EPS Estimate | USD -0.26 |
|---|---|
| Revenue Estimate | $4.53M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.27 vs est -0.31 ▲ beat |
| 2025-12-31 | USD -0.27 vs est -0.3 ▲ beat |
| 2025-09-30 | USD -0.31 vs est -0.24 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (CNTB)
| Total Revenue | $2.95M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +5666.70% |
| Gross Margin | +100.00% |
| Operating Margin | -635.98% |
| Profit Margin | +0.00% |
| ROE | -140.51% |
| Debt / Equity | 0.02 |
| Current Ratio | 2.37 |
| Total Cash | $31.49M |
| Total Debt | $596,000 |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | -$51.64M (-80687.5% of revenue) |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (CNTB)
Nexqual rates Connect Biopharma Holdings Limited's overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $31M cash, no debt |
| Cash Flow | Weak — FCF negative: -$52M (FY ended Dec 2025, 10-K), burning cash |
| Efficiency | Critical — ROE -141%, ROA -69.7% |
Ownership (CNTB)
| Insider Ownership | +30.34% |
|---|---|
| Institutional Ownership | +61.36% |
| Shares Outstanding | 62.97M |
| Float | 17.30M |
| Short % of Float | +7.88% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (CNTB)
Connect Biopharma Holdings Limited is led by Barry David Quart Pharm.D. (age 68), CEO & Director, per Nexqual as of October 16, 2026 at 05:22 UTC.
| CEO & Director | Barry David Quart Pharm.D. (age 68) |
|---|---|
| President | David L. Szekeres (age 51) |
| Senior Vice President of Finance | Lisa Peraza (age 48) |
| Vice President of Human Resources | Sean T. Ristine (age 55) |
| Senior Vice President of Clinical Development(Consultant) | Srikanth Pendyala |
Major Backers & Investors (CNTB)
Notable institutional backers of Connect Biopharma Holdings Limited include Ikarian Capital, LLC, 683 Capital Management LLC, Boothbay Fund Management, LLC, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Ikarian Capital, LLC | 7.21% |
| 683 Capital Management LLC | 2.04% |
| Boothbay Fund Management, LLC | 1.55% |
| Perceptive Advisors Llc | 1.26% |
| Adar1 Capital Management, LLC | 1.11% |
| BML Capital Management, LLC | 0.91% |
| SilverArc Capital Management, LLC | 0.87% |
| Richmond Brothers, Inc. | 0.85% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 2.67% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt